Yazar "Alkis, N." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure
    (Zerbinis Medical Publ, 2011) Alkis, N.; Demirci, U.; Benekli, M.; Yilmaz, U.; Isikdogan, A.; Sevinc, A.; Ozdemir, N. Y.
    Purpose: To retrospectively evaluate the efficacy and tolerability of mitomycin-C (MMC) in combination with fluoropyrimidines as salvage 3rd -or 4th-line therapy in metastatic colorectal cancer (MCRC) patients. Methods: All patients in this study had previously failed oxaliplatin and irinotecan-based chemotherapy. Patients were treated with MMC (6 mg/m(2) intravenously/i.v) on day 1 in combination with either oral UFT (500 mg/m(2)) and oral leucovorin (LV) (30 mg) on days 1-14 every 3 weeks (group A) or infusional 5-fluorouracil (5-FU) by deGramont regimen with i.v. LV (200 mg/m(2)) on days I and 2, every 2 weeks (group B). Results: Thirty-nine MCRC patients were analyzed. Twenty-two of them were in group A and 17 in group B. Thirty-three were evaluable for clinical efficacy The clinical benefit in the intent-to-treat (ITT) population was 30.8%. Median progression free survival (PFS) was 6 months (95% confidence interval/CI 4-8) and median overall survival (OS) 9 months (95% CI 6.5-11.5). Median PFS was 3 months (95% CI 2.4-3.6) in group A and 7 months (95% CI 5.1-8.9) in group B (p=0.009). Median OS was 7 months (95% CI 4.3-9.7) in group A and 12 months (95% CI 5.4-18.6) in group B (p=0.422). The combination of MMC and fluoropyrimidines was generally well tolerated. The most common severe toxicities were nausea and vomiting, neutropenia, hepatotoxicity and diarrhea. Conclusion: MMC in combination with fluoropyrimidines is safe and active in heavily-pretreated MCRC patients. This combination remains a viable option in these patients. However better therapies are urgently needed.
  • [ X ]
    Öğe
    Outcome of operable male breast carcinoma: One hundred eighteen patients
    (Amer Soc Clinical Oncology, 2011) Arslan, U. Yalcintas; Oksuzoglu, O. B.; Ozdemir, N.; Aksoy, S.; Alkis, N.; Durnali, A. Gok; Kaplan, M. A.
    [Abstract Not Available]
  • [ X ]
    Öğe
    PROGNOSTIC FACTORS AND TREATMENT OUTCOMES OF PATIENTS WITH UTERINE LEIOMYOSARCOMA: A RETROSPECTIVE STUDY OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY
    (Oxford Univ Press, 2012) Durnali, A.; Tokluoglu, S.; Ozdemir, N.; Inanc, M.; Alkis, N.; Zengin, N.; Sonmez, O. U.
    [Abstract Not Available]